Abstract
A 55-year-old man was initially given a diagnosis of chronic lymphocytic leukemia (CLL) in April 1994 at age 44 years. After a period of observation, he was treated for progressive disease with chlorambucil in 1996 and again in 2002. In 2003, a prognostic marker evaluation showed that his CLL cells displayed “high-risk” biologic factors (unmutated Ig heavy chain variable region, and expression of CD38 and ζ-chain-associated protein 70) for progressive disease.1 The patient then developed cytopenia and was treated for progressive CLL in October 2003 with one cycle of high-dose dexamethasone (200 mg m−2 day−1 × 5 days) and rituximab (375 mg m−2 week−1 × 4 weeks) (Rituxan; Biogen Idec, Inc.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
